A Fast Fish with
a Huge Impact on Cancer and Metabolic
Disease Therapeutics
EVENT
ImmunoForge has received ~1.5M USD funding from Korea Drug Development Fund
August 13, 2019
PhaseBio, a NASDAQ-registered Company, Announces Global License of PB1023 to ImmunoForge
April 9, 2019
Elasmogen, a UK Biopharma Company, Announces License Agreement with ImmunoForge
January 16, 2019
ABOUT
PIPELINE
EVENT
CONTACT
More
